RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Status:
Recruiting
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary
efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the
treatment of locally advanced solid tumors with HER2 expression